When a cancer survivor’s story becomes a sales pitch

When a public figure speaks about cancer, people listen differently. For patients and families navigating diagnosis, treatment and uncertainty, the story of someone who has survived can offer hope. But that trust also carries responsibility. When a personal cancer journey becomes the opening pitch for a commercial health product, the line between inspiration and influence can become dangerously thin.

That is the question raised by former India cricketer Yuvraj Singh’s new venture, PROTOCOL32, and the medical backlash that followed its launch. The issue is the evidence behind the claims, the risks consumers may not appreciate, and the responsibility that comes with public trust.

Announcing PROTOCOL32 on October 30, Yuvraj recalled playing the 2011 World Cup while battling cancer. “In 2011, I played the World Cup with cancer. Nobody knew. Neither did I. Now I take my daily health very seriously. So should the entire India,” he wrote.

View this post on Instagram

A post shared by Yuvraj Singh (@yuvisofficial)

He described the product as a daily sachet combining “32 FSSAI-approved supplements”, intended to support multiple functions in the body. It claims to support functions ranging from energy and immunity to brain, heart and liver health. 

It was the juxtaposition of his cancer story with the product pitch that particularly troubled some doctors. Dr Rishabh Jain, an oncologist at AIIMS Delhi, wrote: “It hurts to read a post that opens with your cancer story and ends by selling a daily sachet.” He warned that telling people even two or three supplements were not enough to “run the body” could make followers feel they were putting their families’ health at risk by not buying the product.

Doctors warn that FSSAI approves supplements on the basis of their content, not on their effectiveness. 

An oncologist associated with a civic hospital in Mumbai says, “A celebrity’s recovery is not evidence that a supplement can prevent disease or deliver broad health benefits. Nor should consumers be made to feel that good health depends on buying an elaborate daily regimen.”

The science under scrutiny

Hepatologist Dr Cyriac Abby Philips, widely known on X as The Liver Doc, was among the sharpest critics. He described the promotion as the “business of bad science” and questioned the evidence behind the product’s health claims. He also flagged potential concerns around the combination of ingredients, including ashwagandha, bacopa, curcumin and boswellia, which he said have been implicated in cases of liver injury.

Dr C S Pramesh, director of Tata Memorial Hospital, also questioned the evidence and appealed to Yuvraj to recognise the influence he commands. “You have a major following, and you need to be wise about how you use it,” he wrote. “Please don’t allow the lure of money to betray your followers.”

Dr Philips has questioned whether evidence for separate nutrients can substantiate claims for a combination of 32 ingredients, whether several are present at doses supported by human trials, and whether their interactions have been adequately assessed. He has also challenged the brand’s statement that a clinical trial is underway, asking for details of its registration. These are expert criticisms, not established findings, and require a transparent, evidence-based response.

PROTOCOL32 has pushed back. The brand said it is intended for healthy adults, not people with cancer, and that it has never claimed otherwise. It said the ingredient quantities and supporting research are disclosed, that every ingredient is within FSSAI-permitted limits, and that a clinical trial is underway whose results will be published. It also acknowledged that some criticism was fair and said it would improve where necessary.

Permission to use an ingredient in a supplement is not the same as proof that a finished formulation delivers all the health outcomes suggested by its marketing. Evidence for an ingredient at one dose cannot automatically validate a different dose or a combination with dozens of other compounds. What benefit has this exact formulation demonstrated, at what dose, for whom and over what period?

A familiar warning about celebrity influence

This is not the first time a high-profile cricketing figure’s comments on cancer have triggered a medical response. In 2024, Navjot Singh Sidhu spoke about dietary and lifestyle measures, including neem and turmeric, in connection with his wife’s recovery from stage-four breast cancer.

 A statement signed by 262 current and former Tata Memorial oncologists rejected the suggestion that such measures could cure cancer, stressing that there was no high-quality evidence to support them as cancer treatments. Sidhu later clarified that the dietary changes were made in consultation with doctors and were intended to support treatment.

Nutrition alongside medical care is not the same as a cure. Celebrity testimonials can blur that distinction when audiences encounter them without medical context.

Such precedents become troublesome, especially when India recorded an estimated 1.41 million new cancer cases and more than 916,000 cancer deaths in 2022, according to the International Agency for Research on Cancer. In this context, health misinformation can deepen anxiety, encourage unnecessary consumption and, in the worst cases, divert patients from evidence-based care.

The consequences of such claims can extend beyond misinformation. In an article titled “Punjab Has a Sidhu Problem”, published in Oncology Corner on Substack on June 11, 2026, oncologist Dr Wajahat Ahmed argues that the more insidious danger of such advertisements is treatment delay. A patient influenced by a viral celebrity testimonial may not reject medical care outright but decide to try a diet or home remedy for a few weeks before seeking treatment. In cancer care, that delay can alter treatment options and outcomes. As Dr Ahmed puts it, “A survivor’s testimony is hope; it is not a protocol.”

Dr Ahmed also places the controversy in the context of Punjab’s strained cancer-care infrastructure, particularly in its Malwa belt. He argues that when specialist care is distant or inaccessible, affordable home remedies and celebrity survival stories can fill the vacuum left by the healthcare system. 

His criticism extends beyond Sidhu to the media ecosystem that gives celebrity claims enormous reach while medical rebuttals struggle to find the same audience. His central message is stark: “Diet can support your treatment. It cannot replace it.”

The law already recognises the dangers of misleading health claims. The Drugs and Magic Remedies (Objectionable Advertisement) Act, 1954, restricts advertisements for drugs claiming to treat or prevent specified diseases, while consumer protection rules place responsibilities on advertisers and endorsers to avoid misleading claims. But the ethical test should be higher than merely avoiding an explicit claim to cure cancer.

“A celebrity need not be a doctor. But when a personal story gives a product its emotional force, the endorser cannot treat that story as just another marketing asset. Brands must substantiate what they promise; celebrities must understand what their audiences may infer. And doctors must be heard when they ask for evidence,” said a creative agency head. 

Hope can help people endure cancer. It should never be packaged as a sales pitch.

Endorsement of Tobacco & other harmful products 

Celebrity influence in India extends beyond health and wellness marketing. Several film stars have also faced regulatory scrutiny over alleged surrogate advertising for tobacco and pan masala products—categories associated with serious health risks, including oral cancer.

In August 2026, the Maharashtra FDA issued show-cause notices to Shah Rukh Khan, Ajay Devgn and Tiger Shroff over their association with Vimal Elaichi advertisements, alleging that the campaigns indirectly promoted Vimal Pan Masala. The actors and company disputed the allegations. The episode raises a broader question about the responsibility of celebrities when their endorsements may help circumvent restrictions on advertising certain products.

From sugary drinks and unhealthy packaged foods to cryptocurrency platforms, betting apps and alleged surrogate promotions for tobacco and pan masala, Indian celebrities have increasingly become the public face of products and services that invite questions about consumer welfare. 

The categories may differ, but the larger concern remains the same: how much responsibility should public figures bear when their influence is used to sell products that may carry health, financial or social risks?